VistaGen Therapeutics
VTGN
21 hedge funds and large institutions have $2.36M invested in VistaGen Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.24% less ownership
Funds ownership: 0.49% → 0.25% (-0.24%)
16% less funds holding
Funds holding: 25 → 21 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
70% less capital invested
Capital invested by funds: $7.99M → $2.36M (-$5.62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$89.6K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$38.3K |
| 3 |
LPL Financial
San Diego,
California
|
+$33.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.66M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.19M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$462K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$203K |
| 5 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Jane Street
New York
| – | -$29K | -745 | Closed |
|
27
Koshinski Asset Management
Decatur,
Illinois
| – | -$26 | -667 | Closed |
|
|
HP
28
Hikari Power
Tokyo,
Japan
| – | -$14K | -355 | Closed |
|
VTGN Hedge Fund Activity: Q2 2019 in Review
21 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2019, worth a combined $2.36M — down 70% from $7.99M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VTGN and 3 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was HighTower Advisors, adding an estimated $89.6K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.66M sold.
- 21 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2019, down from 25 in Q1 2019.
- Funds reported $2.36M of VistaGen Therapeutics stock for Q2 2019, down 70% quarter-over-quarter.
- 3 funds opened new VistaGen Therapeutics positions in Q2 2019 and 7 closed out, a net change of -4 holders.
- The largest VistaGen Therapeutics buyer in Q2 2019 was HighTower Advisors, an estimated $89.6K added.
- The largest VistaGen Therapeutics seller in Q2 2019 was Point72 Asset Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q2 2019.